-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Research Background:
Thalassemia syndrome is a recessive, inherited hemoglobinopathy characterized
Research Objectives:
A new deferasirox film-coated tablet (DFX FCT) is designed to provide a more convenient mode of administration and better tolerability
Research Methods:
This study is a prospective observational study of the safety and efficacy of DFX FCT in pediatric patients
Results of the study:
A total of 25 pediatric patients were selected
Conclusion of the study:
Overall, the use of DFX FCT proved safe in older children, but younger patients experienced adverse events – particularly an increase in liver enzyme values that did not respond
References:
Adramerina A, Printza N, Hatzipantelis E, Symeonidis S, Tarazi L, Teli A, Economou M.